Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2011 6
2012 9
2013 13
2014 10
2015 9
2016 8
2017 6
2018 18
2019 15
2020 23
2021 25
2022 23
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kanto imajo (1 results)?
Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis.
Kumada T, Toyoda H, Ogawa S, Gotoh T, Suzuki Y, Imajo K, Sugimoto K, Kakegawa T, Kuroda H, Yasui Y, Tamaki N, Kurosaki M, Izumi N, Akita T, Tanaka J, Nakajima A. Kumada T, et al. Among authors: imajo k. Ultrasonography. 2024 Mar;43(2):121-131. doi: 10.14366/usg.23194. Epub 2023 Dec 11. Ultrasonography. 2024. PMID: 38316132 Free PMC article.
Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease.
Iwaki M, Kessoku T, Tanaka K, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A, Yoneda M. Iwaki M, et al. Among authors: imajo k. Hepatol Commun. 2023 Oct 31;7(11):e0285. doi: 10.1097/HC9.0000000000000285. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37902528 Free PMC article.
Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
Kobayashi T, Iwaki M, Nogami A, Kawamura N, Honda Y, Ogawa Y, Imajo K, Yoneda M, Saito S, Nakajima A. Kobayashi T, et al. Among authors: imajo k. J Gastroenterol. 2024 Jan;59(1):56-65. doi: 10.1007/s00535-023-02049-9. Epub 2023 Oct 16. J Gastroenterol. 2024. PMID: 37845417 Free PMC article.
Multivariable Quantitative US Parameters for Assessing Hepatic Steatosis.
Kuroda H, Oguri T, Kamiyama N, Toyoda H, Yasuda S, Imajo K, Suzuki Y, Sugimoto K, Akita T, Tanaka J, Yasui Y, Kurosaki M, Izumi N, Nakajima A, Fujiwara Y, Abe T, Kakisaka K, Matsumoto T, Kumada T. Kuroda H, et al. Among authors: imajo k. Radiology. 2023 Oct;309(1):e230341. doi: 10.1148/radiol.230341. Radiology. 2023. PMID: 37787670
Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.
Kim BK, Bernstein N, Huang DQ, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, Nguyen K, Nguyen L, Le T, Madamba E, Richards L, Valasek MA, Behling C, Sirlin CB, Nakajima A, Loomba R. Kim BK, et al. Among authors: imajo k. Aliment Pharmacol Ther. 2023 Jul;58(2):229-237. doi: 10.1111/apt.17564. Epub 2023 Jun 2. Aliment Pharmacol Ther. 2023. PMID: 37269117
M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.
Imajo K, Saigusa Y, Kobayashi T, Nagai K, Nishida S, Kawamura N, Doi H, Iwaki M, Nogami A, Honda Y, Kessoku T, Ogawa Y, Kirikoshi H, Yasuda S, Toyoda H, Hayashi H, Kokubu S, Utsunomiya D, Takahashi H, Aishima S, Kim BK, Tamaki N, Saito S, Yoneda M, Loomba R, Nakajima A. Imajo K, et al. Hepatol Res. 2023 Sep;53(9):844-856. doi: 10.1111/hepr.13927. Epub 2023 Jun 15. Hepatol Res. 2023. PMID: 37237426 Free PMC article.
An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography.
Liang JX, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J, Lee DH, Ehman RL, Rorsman F, Vessby J, Lacalle JR, Mózes FE, Pavlides M, Anstee QM, Harrison SA, Castell J, Loomba R, Romero-Gómez M; LITMUS Consortium Investigators. Liang JX, et al. Among authors: imajo k. J Hepatol. 2023 Sep;79(3):592-604. doi: 10.1016/j.jhep.2023.04.025. Epub 2023 Apr 29. J Hepatol. 2023. PMID: 37121437 Free article. Review.
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.
Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Lawitz EJ, Harrison SA, Jacobson IM, Imajo K, Gunn N, Halegoua-DeMarzio D, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Loomba R. Abdelmalek MF, et al. Among authors: imajo k. Clin Gastroenterol Hepatol. 2024 Jan;22(1):113-123.e9. doi: 10.1016/j.cgh.2023.04.012. Epub 2023 Apr 23. Clin Gastroenterol Hepatol. 2024. PMID: 37088458 Free article. Clinical Trial.
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.
Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, Lawitz EJ, Gunn N, Imajo K, Ravendhran N, Akahane T, Boone B, Yamaguchi M, Chatterjee A, Tirucherai GS, Shevell DE, Du S, Charles ED, Abdelmalek MF. Loomba R, et al. Among authors: imajo k. Clin Gastroenterol Hepatol. 2024 Jan;22(1):102-112.e9. doi: 10.1016/j.cgh.2023.04.011. Epub 2023 Apr 23. Clin Gastroenterol Hepatol. 2024. PMID: 37088457 Free article. Clinical Trial.
147 results